Keywords: Elan, Royalty Pharma, Unsolicited takeover offer, Investment plan

Elan calls Royalty Pharma approach "highly opportunistic"

Article | 26 February 2013

Print This

The board of Ireland-based drugmaker Elan Corp (NYSE: ELN) has acknowledged the takeover approach from private equity firm Royalty Pharma ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in